Meta analysis of the protective effect and safety of RotaTeq vaccine against rotavirus gastroenteritis in children in high mortality areas in the world
10.3760/cma.j.cn112866-20220305-00052
- VernacularTitle:RotaTeq疫苗在全球高死亡率地区对儿童轮状病毒胃肠炎保护效果和安全性的Meta分析
- Author:
Yuhang WEI
1
;
Rui PENG
;
Mengxuan WANG
;
Tongyao MAO
;
Mingwen WANG
;
Jiaxin FAN
;
Zheng WU
;
Xiaoman SUN
;
Dandi LI
Author Information
1. 甘肃中医药大学公共卫生学院，兰州 730000
- Keywords:
Rotavirus;
Gastroenteritis;
Vaccine;
Protection rate;
Safety
- From:
Chinese Journal of Experimental and Clinical Virology
2023;37(1):106-111
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the protective effect and safety of RotaTeq vaccine on children with rotavirus gastroenteritis (RVGE) in high mortality areas in the world and guide the correct use of RotaTeq vaccine.Methods:The literature on RotaTeq vaccine in high mortality areas in the world published from February 2006 to December 2021 was searched, screened and sorted out according to the exclusion and inclusion criteria, and the data were analyzed by RevMan 5.3, Stata 14.0 and SPSS 26.0 softwares.Results:A total of 5 reports were enrolled, including 63 974 subjects, including 32 092 subjects in the vaccine group and 31 882 subjects in the placebo group. In high mortality areas, the protection rates of RotaTeq vaccine against RVGE, severe rotavirus gastroenteritis (SRVGE) and very severe rotavirus gastroenteritis (VSRVGE) were VE RVGE=35% (95% CI: 28%-41%), VE SRVGE=51% (95% CI: 33%-65%) and VE VSRVGE=64% (95% CI: 41%-78%). The protection rates of SRVGE in Asia and Africa are VE SRVGE=43% (95% CI: 28%-55%) and VE SRVGE=57% (95% CI: 17%-77%), respectively. There was no significant difference in the incidences of serious adverse events (SAEs) between RotaTeq vaccine group and placebo group ( χ2=2.05, P=0.152). Conclusions:RotaTeq vaccine has a certain protective effect on severe and above RVGE with good safety in high mortality areas in the world.
